本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
Largest crypto exchange bridges traditional and crypto assets, unlocking new opportunities for both crypto and TradFi participants ABU DHABI, UAE, Jan. 8, 2026 /PRNewswire/ -- Binance, the largest cryptocurrency exchange by volume and users, today announced the launch of TradFi Perpetual Contracts, an innovative product category enabling users to access traditional assets through USDT-settled perpetual contracts. This expansion of Binance's derivatives offerings unlocks 24/7 access to diversified TradFi market exposure and offers new trading opportunities. Jeff Li, VP of Product at Binance commented, "The launch of TradFi Perpetual Contracts marks a key step in bridging traditional finance and crypto innovation. By providing round-the-clock access to conventional assets with a seamless trading experience, we empower users to diversify and manage their portfolios more effectively. Backed by strong regulatory compliance and trust, this product creates new opportunities for crypto and TradFi traders on Binance." Binance is the first global digital assets trading platform to obtain a comprehensive suite of licenses under the Abu Dhabi Global Market (ADGM) framework, setting a new standard for digital asset regulation. TradFi Perpetual Contracts are offered by Nest Exchange Limited, a Binance entity regulated by the Financial Services Regulatory Authority (FSRA) of ADGM as a Recognized Investment Exchange. The inaugural TradFi Perpetual Contracts, XAUUSDT and XAGUSDT, correspond to the respective precious metals gold and silver. Binance is actively working to expand the offering with more trading pairs to further bridge traditional and crypto markets. This launch opens TradFi instruments to existing crypto users while also welcoming traditional market participants to explore digital assets on the regulated Binance platform. It reinforces Binance's industry-leading commitment to increasing user choices and connecting traditional finance to crypto, all while adhering to high regulatory standards. TradFi perpetual contracts are designed for a simple and seamless trading experience, with no expiry dates and eliminating the need for contract rollovers. Traders can use them to hedge, diversify, and amplify their portfolio strategies across traditional and digital assets. Key Benefits and Features of TradFi Perpetual Contracts 24/7 Traditional Market Exposure: Unlike traditional markets limited to specific trading hours, Binance's TradFi perpetual contracts allow continuous trading, covering pre-market, post-market, and night sessions for global accessibility and flexibility. Simple and Straightforward: Settled in USDT, these TradFi perpetual contracts feature a familiar settlement currency and a fee structure consistent with Binance's current range of perpetual contracts. This offers users a straightforward, cost-effective way to diversify across asset classes on a trusted platform. Leverage to Amplify Trading: Users can amplify their exposure using available leverage, supporting diverse risk profiles and strategies. Robust and Reliable Pricing with Advanced Risk Management:Binance maintains continuous trading even when the underlying assets have limited market hours. To ensure fair and manage off-hour risk, Binance employs sophisticated pricing and risk management mechanisms: Price Index: Aggregates data from multiple vendors, updating every second during market hours. Outside these hours, it remains fixed at the last value to maintain stability. Mark Price: Updates every second during trading hours, applying a smoothed futures price calculated with an Exponentially Weighted Moving Average (EWMA) during off-hours to prevent sudden price swings. Deviation Constraints: Limits divergence between Mark Price and Price Index (for example, ±3% for commodity contracts like XAUUSDT) to effectively manage risk in continuous trading. TradFi Perpetual Contracts are available on Binance's web platform, mobile app, and via API. Users can log into their Binance account, go to Binance Futures, and find the [TradFi] tab located under the symbol search bar to explore the available TradFi Perpetual contracts. Disclaimer: Digital asset prices can be volatile. The value of your investment may go down or up and you may not get back the amount invested. You are solely responsible for your investment decisions and Binance is not liable for any losses you may incur. TradFi Perps are subject to high market risk and price volatility (particularly outside traditional market hours). You may be called upon at short notice to make additional margin deposits or interest payments. If the required margin deposits or interest payments are not made within the prescribed time, your collateral may be liquidated. Moreover, you will remain liable for any resulting deficit in your account and interest charged on your account. All of your margin balance may be liquidated in the event of adverse price movement. Past performance is not a reliable predictor of future performance. TradFi Perps do not represent ownership of the relevant underlying asset. Before trading, you should make an independent assessment of the appropriateness of the transaction in light of your own objectives and circumstances, including the risks and potential benefits. Consult your own advisers, where appropriate. This information should not be construed as financial or investment advice. To learn more about how to protect yourself, visit our Responsible Trading page. For more information, see our Terms of Use, Clearing Rules, Clearing Procedures, Contract Specifications and Risk Warning. About Binance Binance is a leading global blockchain ecosystem behind the world's largest cryptocurrency exchange by trading volume and registered users. Binance is trusted by more than 300 million people in 100+ countries for its industry-leading security, transparency, trading engine speed, protections for investors, and unmatched portfolio of digital asset products and offerings from trading and finance to education, research, social good, payments, institutional services, and Web3 features. Binance is devoted to building an inclusive crypto ecosystem to increase the freedom of money and financial access for people around the world with crypto as the fundamental means. For more information, visit: https://www.binance.com.
TIANJIN, China, Dec. 29, 2025 /PRNewswire/ -- Taoping Inc. (Nasdaq: TAOP) (the "Company"), a provider of innovative smart cloud platform services and solutions, today announced two significant strategic milestones underscoring its accelerating growth trajectory: the establishment of a new corporate headquarters and the signing of US$2 million in smart elevator renewal contracts. As part of its long-term growth and scale strategy, Taoping has officially relocated its corporate headquarters to a more prominent and strategic location in Tianjin, China. The new headquarters is situated in the Tiankai Higher Education Park on the 21st floor of Building 3, Tianjin Science and Technology Plaza, Keyan West Road, Nankai District, Tianjin. This move strengthens Taoping's operational foundation, enhances access to innovation resources, and positions the Company closer to key partners and customers stakeholders. Taoping will continue to maintain an active presence in Shenzhen, China, serving as its southern headquarters and innovation hub. Anchoring this relocation are the newly secured smart elevator renewal contracts valued at US$2 million, awarded to Taoping's newly acquired subsidiary, Skyladder (Tianjin) Technology Development Co., Ltd. The Company expects to complete the project and recognize the full contract value as revenue in the first quarter of 2026, providing near-term revenue visibility and reinforcing execution strength. China's elevator modernization market represents a substantial and rapidly expanding opportunity. According to official data from the State Administration for Market Regulation, China currently has approximately 12 million elevators in operation, with nearly 10% having been in service for more than 15 years. The large-scale renewal of aging elevators has become a national priority, supported by the July 2024 and January 2025 State-issued policy, "Several Measures on Strengthening Support for Large-scale Equipment Renewal and Consumer Goods Trade-in." Backed by favorable government policy, Taoping is addressing longstanding industry pain points through a technology-driven, data- and AI-enabled business model. Moving beyond the traditional single-equipment upgrade approach, Taoping leverages core technologies such as deep IoT perception and AI-powered autonomous decision-making to collect real-time elevator operational data through intelligent sensors. By integrating its proprietary platforms, the Company delivers a comprehensive, full life-cycle smart service system that enhances safety, efficiency, and operational intelligence, creating a clear and differentiated competitive advantage. Mr. Jianghuai Lin, Chairman and Chief Executive Officer of Taoping, commented, "We are excited to be entering 2026 in a strong position for growth as we focus on unlocking greater value for shareholders. China's elevator industry is entering a powerful dual-growth cycle driven by both large-scale renewal demand and comprehensive intelligence upgrades. The deep synergy between Taoping's full life-cycle smart service capabilities and our platform resources significantly strengthens our strategic position in the smart elevator sector. Looking ahead, we will continue to advance our renewal plus integrated operations and maintenance model and leverage our proven success across key cities nationwide as we deliver sustainable long-term value for our shareholders." About Taoping Inc. Taoping Inc. (Nasdaq: TAOP) has a long history of successfully leveraging technology in the development of innovative solutions to help customers in both the private and public sectors to more effectively communicate and market to their desired targets. The Company has built a far-reaching city partner ecosystem and comprehensive portfolio of high-value, high-traffic areas for its products, which are aligned together with Taoping's smart cloud platform, cloud services and solutions, new media and artificial intelligence. For more information about Taoping, please visit http://en.taop.com. You can also follow us on X. Safe Harbor Statement This press release contains "forward-looking statements" that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release, such as statements regarding our estimated future results of operations and financial position, our strategy and plans, and our objectives or goals, are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. We have attempted to identify forward-looking statements by terminology including "anticipates," "believes," "can," "continue," "could," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "should," or "will" or the negative of these terms or other comparable terminology. Our actual results may differ materially or perhaps significantly from those discussed herein, or implied by these forward-looking statements. There are a significant number of factors that could cause actual results to differ materially from statements made in this press release, including: our potential inability to achieve or sustain profitability or reasonably predict our future results, the effects of the global pandemic or other health crisis, the emergence of additional competing technologies, changes in domestic and foreign laws, regulations and taxes, uncertainties related to China's legal system and economic, political and social events in China, the volatility of the securities markets; and other risks including, but not limited to, those that we discussed or referred to in the Company's disclosure documents filed with the U.S. Securities and Exchange Commission (the "SEC") available on the SEC's website at www.sec.gov, including the Company's most recent Annual Report on Form 20-F as well as in our other reports filed or furnished from time to time with the SEC. The forward-looking statements included in this press release are made as of the date of this press release and the Company undertakes no obligation to publicly update or revise any forward-looking statements, other than as required by applicable law.
YONGIN, South Korea, Jan. 15, 2026 /PRNewswire/ -- GCCL, a leading South Korea-based provider of clinical trial sample analysis, and OPIS, a global full-service contract research organization (CRO), have signed a Memorandum of Understanding (MOU) on the sidelines of the 44th Annual J.P. Morgan Healthcare Conference 2026 in San Francisco, USA, to expand their collaboration and strengthen their position in the global clinical trial market. With the rising proportion of multinational clinical trials, sponsors face varying regulatory requirements, clinical environments, and data demands across regions, driving growing demand for tailored CRO services. GCCL and OPIS will address these needs by combining their expertise to deliver integrated solutions that optimize clinical trial planning, sample analysis, and data management, offering comprehensive and customized services for biopharmaceutical companies in Europe and Asia. At the signing ceremony, representatives from both companies discussed establishing a collaborative framework across multiple areas, including joint global clinical trial services, conducting joint projects, development of new business opportunities, and additional initiatives. Through this collaboration, GCCL aims to expand strategic partnerships with global CROs and research organizations, strengthen its capability to deliver fully integrated clinical trial solutions across Asia, Europe, and the Americas, and extend tailored services to a broader range of biopharmaceutical companies. Commenting on the partnership, Giovanni Trolese, Vice President at OPIS, said, "This collaboration combines OPIS's Europe-focused global network with GCCL's clinical trial analysis expertise, creating a significant opportunity to deliver integrated and efficient clinical trial services to clients. We look forward to further expanding the global clinical trial network and continuously enhancing client-focused, innovative solutions through our close collaboration with GCCL." KwanGoo Cho, CEO of GCCL, added, "This MOU represents more than a partnership; it is a strategic collaboration to deliver optimized clinical trial solutions for global biopharmaceutical companies. By leveraging our close cooperation, we aim to maximize operational efficiency and provide tailored solutions to a diverse range of sponsors, generating tangible business synergies." About GCCL GCCL, a subsidiary of the GC Group, is a leading clinical trial sample analysis provider offering an integrated "one-stop lab solution" with central, bioanalysis, and BSL-3 labs under one system. With tailored solutions, GCCL delivers precise and efficient analytical services across all phases of clinical trials, solidifying its position as a trusted partner in new drug development. Leveraging advanced platforms and LIMS, the company supports partners across Asia and beyond with customized and compliant solutions. In recognition of its leadership, GCCL recently received Frost & Sullivan's 2025 Best Practices Customer Value Leadership Award in the Asia-Pacific clinical sample analysis services industry. For more details, visit: https://eng.gccl.co.kr/. About OPIS OPIS was founded in 1998 by medical doctors from the Pharma Industry and is a global clinical CRO with 26 years of experience in a wide range of therapeutic areas. OPIS provides full-service, 360° clinical trial support from study concept creation and protocol development to full project execution, study data handling, and up to study closure, analysis, and reporting. OPIS manages Phase I-IV, interventional, non-interventional, and medical device studies on an international level. OPIS is committed to continuous growth and expansion, and currently has affiliates in 18 countries around the world. For more details, visit: www.opisresearch.com GC Biopharma Contacts (Media) Sohee Kim shkim20@gccorp.com Yelin Jun yelin@gccorp.com Yoonjae Na yjy6520@gccorp.com GCCL Contacts (Media) HyeYeon Woo hywoo@gccorp.com
NINGBO, China, Jan. 15, 2026 /PRNewswire/ -- Recently, Risen Energy and Eco Persona, a Malaysian solar EPC enterprise, held a strategic cooperation signing ceremony. Both parties will jointly develop commercial and industrial rooftop photovoltaic projects in the four northern states of Malaysia. Centered on technological upgrading, this cooperation will prioritize the use of Risen Energy's high-power Heterojunction (HJT) modules, string inverters, and commercial and industrial energy storage cabinets to construct an efficient power generation PV-storage integrated system. Photo of the two parties signing the agreement As the cutting-edge technology in the current photovoltaic field, Risen Energy's Hyper-ion Pro HJT modules have achieved a mass production power output exceeding 740Wp, ranking among the highest power photovoltaic modules globally. Its core advantages are not only reflected in ground applications but also, thanks to its high power-to-weight ratio, excellent radiation resistance, and ultimate thinness potential, it has become a highly anticipated energy solution in the space economy sector, including low-orbit satellite internet and even deep space exploration, providing reliable technical support for space energy development. Since its establishment in 2019, Eco Persona has specialized in the full-lifecycle services of commercial, industrial, and residential PV systems in Malaysia, particularly excelling in customizing manufacturing rooftop solutions. The two parties have a solid foundation for cooperation; in 2025 alone, they successfully delivered several benchmark projects covering multiple locations in Malaysia such as Kedah, Penang, and Johor, with a cumulative installed capacity surpassing the megawatt scale. This cooperation between the two parties relies precisely on Risen Energy's HJT technological advantages to assist Eco Persona in achieving higher power generation efficiency and lower Levelized Cost of Electricity (LCOE) in commercial and industrial rooftop scenarios, making cutting-edge technology benefit more green energy applications. With the acceleration of the global carbon neutrality process, the photovoltaic market in Southeast Asia is experiencing explosive growth. The strategic cooperation between Risen Energy and Eco Persona not only consolidates their leading positions in the Malaysian photovoltaic market but also, through the deep synergy of cutting-edge technology and local services, provides global clients with more efficient and reliable green energy solutions, jointly outlining a blueprint for carbon neutrality.
Total of 945 integrated projects in 2025, including 74 Phase III clinical projects and 25 commercial manufacturing projects 209 new integrated projects in 2025 set a new record, with approximately 50% originating from U.S. clients Complex modalities are WuXi Biologics' core growth engine, with 2/3 of the new integrated projects comprising bispecific/multispecific antibodies and ADCs Bispecific/multispecific antibodies are WuXi Biologics' most exciting, fastest‑growing and highest‑margin engine. With 196 projects in the pipeline, this modality contributes nearly 20% of the company's revenue and delivers 120%+ YoY growth Scaling integrated CRDMO capabilities across the U.S. and Asia, while expanding the global network into the Middle East SAN FRANCISCO, Jan. 15, 2026 /PRNewswire/ -- On January 14, Dr. Chris Chen, CEO of WuXi Biologics, delivered a keynote at the 44th J.P. Morgan Healthcare Conference, highlighting the company's 2025 achievements and outlining its outlook. Dr. Chen commented, "Through the CRDMO model, we have achieved significant advancements spanning discovery, development, and manufacturing. By executing our 'Follow and Win the Molecule' strategy, world-class quality systems, deep technical capabilities and operational excellence, WuXi Biologics has become the partner of choice for biopharmaceutical innovators and MNCs. With the launch of the CRDMO+ strategy, we will further enable client success by scaling global manufacturing capacity, advancing modality innovation, and accelerating speed and execution." Strong Project Funnel Achieving Record High Building on leading technology, proven execution and expanding global reach, WuXi Biologics added 209 new integrated projects in 2025, increasing the total to 945 and reinforcing its position as the partner of choice for biopharma innovators worldwide. Approximately half of the new projects originated from U.S. clients, underscoring strong client trust from the market. The company has excelled in three key areas—bispecific/multispecific antibodies, ADCs, and mAbs—leveraging its deep expertise and fully integrated end-to-end capabilities. Bispecific/multispecific antibody and ADC projects continued to expand rapidly, with each growing by approximately 30% to reach 196 and 252 projects, respectively. Together, these complex modalities now account for nearly 50% of the total pipeline, underscoring strong demand for differentiated biologics. In parallel, the company maintains a deep and diversified base of over 400 mAbs and other protein therapeutics, including multiple multi-billion-dollar franchises in late-stage development and commercial manufacturing. With strength across research, development, manufacturing, bispecific/multispecific antibodies represent WuXi Biologics' most exciting, fastest-growing and highest‑margin modality, contributing nearly 20% of the company's revenue and achieving YoY growth exceeding 120%. Through its "Win-the-Molecule" strategy, WuXi Biologics has been securing a quantity of projects across different stages. In 2025, the company added 23 projects, including 6 Phase III and commercial projects. Notably, half of these projects involve complex modalities, led by bispecific/multispecific antibodies and ADCs. Research: Accelerating Deal Momentum and Platform Inflection Research services maintained strong momentum from 2024 into 2025, with accelerating T‑cell engager (TCE) deals highlighting an inflection point for the company's CD3 platform. The CD3 platform enables bispecific antibodies to retain potent tumor-killing activity against target cells while minimizing cytokine release, optimizing the efficacy-safety balance. It has been widely adopted within the industry, including Merck, GSK, Chia Tai Tianqing Pharmaceutical, and Zai Lab. WuXi Biologics' research services business achieved another record year in 2025, securing record-breaking upfront payments and potential milestone values exceeding USD 4 billion. Development: Pioneering Innovative Solutions WuXi Biologics continues to expand its integrated services through new technology solutions that accelerate timelines, improve product quality and ensure scalable manufacturing. It launched WuXia™ TrueSite, an industry-leading targeted integration (TI)-based CHO cell line platform designed to reshape biologics development by accelerating timelines, enhancing product quality, and ensuring consistent scalability for antibody and complex protein therapies. The platform has achieved an average mAb titer exceeding 8.0 g/L, with over 99% of clonal cell lines maintaining stable protein expression after passaging for 60 generations. The company has also expanded core technology solutions for high-dose delivery into clinical and commercial applications, including High-throughput formulation development platform WuXiHighTM, Hyaluronidase Co-Formulation platform, and large-volume devices capabilities. Manufacturing: Advancing Growth at Speed and Scale As the "Follow and Win the Molecule" strategy continues, the total number of Phase III clinical and commercial manufacturing projects reached 99 in 2025. Manufacturing is positioned for accelerated growth, driven by an expanding commercial portfolio and revenue ramp per program over time. Built on operational excellence, technology leadership and a proven quality system, WuXi Biologics completed 28 PPQs in 2025 and has 34 PPQs scheduled for 2026 based on current contracts, reflecting strong momentum in CMO services. It has achieved a 99%+ success rate on PPQ batches, ranking among the industry's top performers. Since 2017, it has delivered more than 350 large‑scale batches (6,000 L – 16,000 L per batch) for global partners. WuXi Biologics has consistently demonstrated a proven track record of adherence to the industry's rigorous quality standards. As of the end of 2025, the company had successfully passed 46 regulatory inspections, including 22 inspections conducted by the FDA and EMA. The company also holds an industry-leading record with a 100% pass rate for FDA Pre-License Inspection (PLI). In addition, WuXi Biologics passed more than 1,800 GMP quality audits led by clients, including over 230 audits by EU Qualified Persons. Currently, the company operates 15 GMP-certified drug substance and drug product facilities within its global network, with 136 facility license approvals and a 100% success in GMP inspections. Its world-class quality and compliance capabilities remain the cornerstone of clients' trust. Global Layout: Building Strategic Hubs in the U.S., Singapore and Qatar WuXi Biologics is increasing strategic investments in the U.S. to deliver integrated biologics services. By leveraging cross‑site synergies among facilities in New Jersey and Massachusetts, the company enables the seamless transfer of materials, samples, and products across the U.S.. In Singapore, the company has commenced construction of its new modular drug product facility, while the drug substance modular facility is currently in the design phase. Meanwhile, its subsidiary WuXi XDC achieved mechanical completion of its Singapore manufacturing facility in June 2025, positioning the Singapore site as a strategic hub within the global network. In December 2025, WuXi Biologics announced the signing of an MOU with the Qatar Free Zones Authority (QFZ). The long-term strategy is to establish the Qatar site as a strategic pillar within WuXi Biologics' global CRDMO network, marking the company's entry into the region while extending its global footprint and capabilities. Global Leading Digital CRDMO: Powering World-class Speed, Quality, Operational Efficiency and Client Experience WuXi Biologics has embedded digital innovations into every fabric of research, development, manufacturing, operations and customer engagement that truly redefined values for its partners. The DaVinci Client Portal provides a secure, real-time interface for proposal generation, access to experimental and manufacturing data and reports, cost estimates, and shipment tracking. Lab core systems, such as BioFoundry and InSilico, accelerate discovery, development and manufacturing by enabling digital twins, in‑silico modeling and predictive decision-making. By leveraging smart manufacturing solutions, such as Electronic Batch Record (EBR), the company has driven an approximately 40% productivity gain and ensured data integrity and high product quality, while advanced planning systems have delivered about a 20% improvement in efficiency. Recently, WuXi Biologics launched the industry-leading digital twin platform PatroLabTM to enhance process performance, minimize process risks, shorten development timelines, and ensure consistent, high-quality biologics manufacturing. A Leader in Industry Sustainability As a participant of the United Nations Global Compact (UNGC), WuXi Biologics has made significant strides in sustainability, earning widespread industry recognition. The company was granted an MSCI AAA Rating; awarded an EcoVadis Platinum Medal; listed in the Dow Jones Sustainability Indices (DJSI); named to the CDP "A List" for Climate Change, Water Security, Supplier Engagement Assessment; given the highest negligible-risk rating by Sustainalytics, and recognized as a Sustainalytics industry and regional ESG top-rated company for five consecutive years; selected as a Constituent of the FTSE4Good Index Series; listed in the Hang Seng ESG 50 Index; and rated as Prime by ISS ESG Corporate Rating. Sustainable High Growth in 2026 In 2026, WuXi Biologics will build on strong momentum with accelerated growth driven by robust research, leading development and explosive manufacturing business. By putting clients first and leveraging its full end‑to‑end capabilities, WuXi Biologics is fast‑tracking biologics innovation for global clients and delivering meaningful benefits to patients around the world. About WuXi Biologics WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide. With over 12,000 skilled employees in China, the United States, Ireland, Germany, Singapore and Qatar, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of December 31, 2025, WuXi Biologics is supporting 945 integrated client projects, including 74 in Phase III and 25 in commercial manufacturing. WuXi Biologics regards sustainability as the cornerstone of long-term business growth. The company continuously drives green technology innovations to offer advanced end-to-end Green CRDMO solutions for its global partners while consistently achieving excellence in Environment, Social and Governance (ESG). Committed to creating shared value, it collaborates with all stakeholders to foster positive social and environmental impacts and promote responsible practices that empower the entire value chain. For more information about WuXi Biologics, please visit: www.wuxibiologics.com. Contacts MediaPR@wuxibiologics.com Businessinfo@wuxibiologics.com
SINGAPORE, Jan. 15, 2026 /PRNewswire/ -- JIOS Aerogel (JIOS), a global leader in silica aerogel technology, today announced that its Korean manufacturing licensee has secured a major contract to supply Thermal Blade® thermal runaway barriers for Hyundai and Kia's next-generation and Purpose Built Vehicle (PBV) models. This milestone represents the first contract delivered under JIOS's "Hub & Spoke" business model, which licenses the production of finished thermal barriers to experienced automotive suppliers located near end customers. The contract was awarded following a formal Hyundai Motor Group tender. Mass production is scheduled to commence in June 2027, spanning a projected 12-year period. JIOS anticipates significant order volumes over the mid-to-long term as Hyundai expands its electric vehicle lineup. This partnership validates JIOS's technology at the highest tier of the automotive industry while ensuring long-term, predictable revenue through its regional manufacturing network. Introduced in 2025, the "Hub & Spoke" model centralizes core aerogel powder production at JIOS's Korea facility (the Hub) to maintain strict quality and cost controls. These proprietary powders are then supplied to a global network of licensees (the Spokes) who handle high-volume Thermal Blade® manufacturing. This structure allows JIOS to support regional supply chains and meet localized production requirements without the capital intensity of building and operating multiple downstream assembly plants worldwide. "By separating upstream powder production from downstream assembly, JIOS can scale revenue without repeated heavy investment in new facilities," said Stephen Kang, CEO and Co-Founder of JIOS. "Our licensees manage the local assembly footprint, allowing JIOS to build a global network that scales faster than our vertically integrated peers. This capital-efficient approach preserves our resources for high-value technology development while ensuring our business grows in lockstep with global EV demand." With facilities in Singapore and Korea, JIOS is strategically positioned to help automakers reduce dependence on traditional supply chains. "Our footprint aligns with the industry trend of localized manufacturing close to final assembly points," added James Lee, Chairman and Co-Founder. "We are delighted that our first licensee has secured this contract with Hyundai. This success provides a proven blueprint as we finalize similar partnerships with manufacturers in other key automotive regions." About JIOS Aerogel JIOS Aerogel (JIOS) is the world's leading manufacturer of silica aerogel powder. Headquartered in Singapore, the company was founded in 2013 to pioneer a new process that dramatically lowers the cost of aerogel production. JIOS is on a mission to accelerate the adoption of aerogels to improve the safety and performance of electric-vehicle (EV) batteries. Recognised globally as the premier technology for mitigating thermal runaway in lithium-ion batteries, aerogels provide an ultra-thin insulation layer between battery cells, offering exceptional thermal protection at high temperatures. For more information, visit www.jiosaerogel.com.
A12 藝術空間
Contracts
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
